MedTrace Logo

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

NCT03316586 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-12-28

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer.

The drugs involved in this study are:

* Cabozantinib (XL184)
* Nivolumab

Conditions

Interventions

DRUG

Nivolumab

Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.

DRUG

Cabozantinib

Cabozantinib may help to shrink or stabilize breast cancer

Sponsors & Collaborators

Principal Investigators

  • Sara Tolaney, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2019-08-30
Completion
2019-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316586 on ClinicalTrials.gov